Mylan Pharmaceuticals Inc. received FDA approval for its generic version of the cardiovascular drug Amlodipine and Atorvastatin, offering a cost-effective alternative to branded combination therapies. This approval is expected to intensify competition and exert downward pressure on market prices as patients seek accessible treatment options.